Academic Journal of Second Military Medical University (第二军医大学学报) 2015/36:12 PP.1348-1351
Objective To study the clinical effect of famitinib malate for treatment of metastatic renal cell carcinoma (mRCC). Methods Nine mRCC patients treated with famitinib malate in our center completed their follow-up from October 2011 to June 2015. The patients received famitinib malate at an initial dose of 25 mg, which was given orally before breakfast once a day. One cycle consisted of 42 days. The antitumor efficacy and the adverse event (AE) were observed. Results After treatment with famitinib for 3 cycles, the objective response rate (ORR) reached 66.7% (6/9) for the patients, with partial remission (PR) found in 6 patients, stable disease (SD) in 2 patients and progressive disease (PD) in 1.The median follow-up time was 29 months (15-40 months) in our study and the median progression free survival (PFS) was 16.5 months (4.5-38.0 months). The most common treatment-related AE of famitinib malate was proteinura, and other AEs were similar to those of sunitinib. Six patients had reduction and interruption as appropriate due to AEs, and 2 patients stopped the treatment due to intolerable proteinuria. Conclusion Famitinib malate has a good antitumor activity upon mRCC, and its adverse reaction is controllable, making it a promising molecule-targeted drug for clinical application.
 周爱萍, 张 雯, 常春晓, 迟·依荷巴丽, 王金万.苹果酸法米替尼Ⅰ期临床人体耐受性研究初步总结[J].中国新药杂志, 2011, 20:1678-1682, 1690.
 Moeh H. Cystic renal tumors:new entities and novel concepts[J]. Adv Anat Pathol, 2010, 17:209-214.
 张洪秀, 聂明秀, 李 伟. 晚期肾癌靶向治疗现状[J].现代泌尿生殖肿瘤杂志, 2014, 6:375-377.
 Sternberg C N, Calabrò F, Bracarda S, Cartenì G, Lo Re G, Ruggeri E M, et al. Safety and efficacy of sunitinib in patients from Italy with metastatic renal cell carcinoma: final results from an expanded-access trial[J].Oncology, 2015, 88:273-280.
 Gore M E, Szczylik C, Porta C, Bracarda S, Bjarnason G A, Oudard S, et al. Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma[J]. Br J Cancer, 2015, 113:12-19.
 Kim K H, Kim H Y, Kim H R, Sun J M, Lim H Y, Lee H J, et al. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with renal insufficiency[J]. Eur J Cancer, 2014, 50:746-752.
 Park S J, Lee J L, Park I, Park K, Ahn Y, Ahn J H, et al. Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma[J]. Chemotherapy, 2012, 58:468-474.
 Miyake H, Miyazaki A, Harada K, Fujisawa M. Assessment of efficacy, safety and quality of life of 110 patients treated with sunitinib as first-line therapy for metastatic renal cell carcinoma: experience in real-world clinical practice in Japan[J]. Med Oncol, 2014, 31:978.
 Gore M E, Szczylik C, Porta C, Bracarda S, Bjarnason G A, Oudard S, et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial[J]. Lancet Oncol, 2009, 10:757-763.
 Lacovelli R, Alesini D, Palazzo A, Trenta P, Santoni M, de Marchis L, et al.Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trials[J]. Cancer Treat Rev, 2014, 40:271-275.
 Motzer R J, Hutson T E, Tomczak P, Michaelson M D, Bukowski R M, Oudard S, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma[J]. J Clin Oncol, 2009, 27:3584-3590.